Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation
Cancers · 08.04.2023 · 15 (8) · 2206
DOI: 10.3390/cancers15082206 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 08.04.2023. Verfasst von Eleonora Sosa Cuevas und 2 weiteren Autor:innen. Beteiligte Einrichtung: EFS AuRA, R&D Laboratory, 38000 Grenoble, France. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Etablissement Français du Sang (EFS) AuRA, Ligue contre le Cancer, Société Française de Dermatologie (SFD.
Abstract (Originalsprache)
Evasion from immunity is a hallmark of cancer development. Dendritic cells (DCs) are strategic immune cells shaping anti-tumor immune responses, but tumor cells exploit DC versatility to subvert their functions. Unveiling the puzzling role of DCs in the control of tumor development and mechanisms of tumor-induced DC hijacking is critical to optimize current therapies and to design future efficient immunotherapies for melanoma. Dendritic cells, crucially positioned at the center of anti-tumor immunity, represent attractive targets to develop new therapeutic approaches. Harnessing the potencies of each DC subset to trigger appropriate immune responses while avoiding their subversion is a challenging yet promising step to achieve tumor immune control. This review focuses on advances regarding the diversity of DC subsets, their pathophysiology and impact on clinical outcome in melanoma patients. We provide insights into the regulation mechanisms of DCs by the tumor, and overview DC-based therapeutic developments for melanoma. Further insights into DCs’ diversity, features, networking, regulation and shaping by the tumor microenvironment will allow designing novel effective cancer therapies. The DCs deserve to be positioned in the current melanoma immunotherapeutic landscape. Recent discoveries strongly motivate exploitation of the exceptional potential of DCs to drive robust anti-tumor immunity, offering promising tracks for clinical successes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- EFS AuRA, R&D Laboratory, 38000 Grenoble, France.
- Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Team: Epigenetics, Immunity, Metabolism, Cell Signaling and Cancer, Université Grenoble Alpes, 38000 Grenoble, France.
ORCID-Profile: Eleonora Sosa Cuevas, Philippe Saas, Caroline Aspord
Förderung
- Etablissement Français du Sang (EFS) AuRA
- Ligue contre le Cancer
- Société Française de Dermatologie (SFD
- GEFLUC
- Fondation BMS
- Université Grenoble Alpes (UGA)
- Société Française de Dermatologie (SFD)
Zitieren
APA
Sosa Cuevas, E., Saas, P., & Aspord, C. (2023). Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation. Cancers, 15(8), 2206. https://doi.org/10.3390/cancers15082206
Vancouver
Sosa Cuevas E, Saas P, Aspord C. Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation. Cancers. 2023;15(8):2206. doi:10.3390/cancers15082206
BibTeX
@article{SosaCuevas2023,
author = {Sosa Cuevas, Eleonora and Saas, Philippe and Aspord, Caroline},
title = {Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation},
journal = {Cancers},
year = {2023},
volume = {15},
number = {8},
pages = {2206},
doi = {10.3390/cancers15082206}
}
EUVIMED